EUVIMEDEUVIMED entdecken
Open Access

Impact of radiotherapy on quality of life in patients with rectal cancer

Patricia Tejedor iD, Quentin Denost

BJS Open · 2024

DOI: 10.1093/bjsopen/zrae105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJS Open, 2024. Verfasst von Patricia Tejedor und 1 weiteren Autor:innen. Beteiligte Einrichtung: Colorectal Surgery Unit, General University Hospital Gregorio Marañón, Madrid, Spain. Hauptthemen laut MEDLINE: Rectal Neoplasms, Quality of Life. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiotherapy (RT) has been shown to decrease the rate of local recurrence (LR) in rectal cancer1,2. However, with the advent of the total mesorectal excision (TME) technique on one side and the widespread use of neoadjuvant chemotherapy on the other side, the necessity of RT for local disease control has been questioned. In the case of locally advanced rectal cancer with a predicted free circumferential resection margin (CRM), there is ongoing debate about whether the benefits of pelvic RT outweigh the potential harms, particularly concerning functional outcomes. In this issue of BJS Open, Malik et al.3 aimed to evaluate long-term quality of life (QoL) in patients with rectal cancer treated with RT. This nationwide LaTE study, conducted in Norway over a 13-year interval, included 2142 eligible patients, 36% of whom received neoadjuvant RT. The study aimed to discern differences in QoL and functional outcomes between patients receiving neoadjuvant RT and those who did not, utilizing a comprehensive survey with 107 questions, including the gastrointestinal quality of life index, 36-item short form health survey, low anterior resection syndrome score, and scale for chemotherapy-induced long-term neurotoxicity questionnaires. Malik et al.3 used a propensity score model to obtain comparable groups and concluded that QoL was significantly lower in recurrence-free patients who received RT compared with those who did not. Current concerns in rectal cancer management are distant metastases, organ preservation, and bowel function associated with QoL. Over recent years, several randomized phase III trials evaluating total neoadjuvant therapy (TNT) have been published, but the appropriate selection of patients for TNT remains controversial. RT is a common component of these treatment protocols and has demonstrated considerable benefits for high-risk patients. For instance, the PRODIGE 23 trial4,5 included cT3 or cT4 patients and reported a significant improvement in both 5-year disease-free and overall survival in the group receiving induction chemotherapy followed by chemoradiotherapy. At the same time, the RAPIDO trial6 found an increased risk of LR in the short-course RT followed by chemotherapy arm compared with the long-course chemoradiotherapy arm (10% versus 6%). These findings underscore the critical role of RT in managing high-risk patients, irrespective of their eligibility for sphincter-saving surgery. Moreover, TNT has been shown to increase pathological complete response rates compared to traditional chemoradiotherapy4,6–10, emphasizing the crucial role of RT in facilitating organ preservation strategies through an opportunistic approach. However, for patients considered low risk based on MRI features and who are candidates for sphincter-saving surgery, the management approach can be different. A recent prospective trial evaluated the selective use of neoadjuvant chemoradiotherapy in patients with high-risk rectal cancer and compared the outcomes with a group of low-risk patients undergoing upfront surgery; for the low-risk group, the 5-year rates of LR and distant metastases were 2.9% and 15.9% respectively11. These findings are consistent with previous data from retrospective studies12,13. However, for low-risk patients, organ preservation strategies for those who have a good response to chemoradiotherapy have shown similar oncological results compared with TME upfront14 or TME after chemoradiotherapy15. For this selective approach (organ preservation for low-risk patients), appropriate selection of patients who should receive either chemoradiotherapy or TNT should take place. The results pending from GRECCAR 12 will likely provide the first answers. More recently, the PROSPECT trial16 included 1128 patients with clinical stage T2 N1 or T3 N0–1 (considered low risk). Half of the patients were randomized to initial chemoradiotherapy and the other half received induction chemotherapy with six cycles of FOLFOX. In the latter group, patients achieving greater than or equal to 20% tumour shrinkage proceeded to surgery without RT, followed by adjuvant chemotherapy. Consequently, 90% of patients in this arm avoided RT. The 5-year disease-free survival rates did not differ significantly between the two study arms (80.8% in the FOLFOX group and 78.6% in the chemoradiotherapy group), with similar 5-year LR rates (1.8% versus 1.6%) and overall survival rates (89.5% versus 90.2%). Notably, this trial also indicated better QoL for patients not receiving RT, corroborating the findings of Malik et al.3. At 12 and 18 months post-surgery, the PROSPECT trial reported significantly higher rates of fatigue, neuropathy, and sexual dysfunction among patients who received chemoradiation17. De-escalation in rectal cancer management refers to strategies aimed at reducing the impact of treatment on QoL, while still achieving effective local and systemic disease control. With this in mind, and in the case of a predicted free CRM, radiation should be used to avoid surgery in organ preservation strategies, otherwise TME with or without neoadjuvant chemotherapy should be proposed. The selective use of neoadjuvant RT is pivotal in ensuring that its benefits are maximized for patients with more advanced rectal cancers, while minimizing unnecessary exposure for those who may not have a significant benefit. This evolving trend highlights the importance of tailoring treatment strategies to individual patient risk factors and tumour characteristics. Such personalized approaches are essential in optimizing outcomes and preserving QoL by addressing the specific needs of each patient. The authors have no funding to declare. The authors declare no conflict of interest.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rectal NeoplasmsQuality of LifeHumansMaleFemaleAgedMiddle AgedSurveys and Questionnaires

Autor:innen und Institutionen

  • Colorectal Surgery Unit, General University Hospital Gregorio Marañón, Madrid, Spain.
  • Bordeaux Colorectal Institute, Clinique Tivoli, Bordeaux, France.

ORCID-Profile: Patricia Tejedor

Zitieren

APA

Tejedor, P., & Denost, Q. (2024). Impact of radiotherapy on quality of life in patients with rectal cancer. BJS Open. https://doi.org/10.1093/bjsopen/zrae105

Vancouver

Tejedor P, Denost Q. Impact of radiotherapy on quality of life in patients with rectal cancer. BJS Open. 2024. doi:10.1093/bjsopen/zrae105

BibTeX
@article{Tejedor2024,
  author = {Tejedor, Patricia and Denost, Quentin},
  title = {Impact of radiotherapy on quality of life in patients with rectal cancer},
  journal = {BJS Open},
  year = {2024},
  doi = {10.1093/bjsopen/zrae105}
}
Kostenlos starten →